Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma

Journal of Clinical Oncology

Volumn 34, Issue 3, 2016, Pages 235-243

  Van Nimwegen, Frederika A ^a   Schaapveld, Michael ^a,b   Cutter, David J ^g,h   Janus, Cècile P M ^d   Krol, Augustinus D G ^e   Hauptmann, Michael ^a   Kooijman, Karen ^a   Roesink, Judith ^c   Van Der Maazen, Richard ^f   Darby, Sarah C ^a   Aleman, Berthe M P ^a   Van Leeuwen, Flora E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Netherlands Comprehensive Cancer Organization   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART VOLUME; HODGKIN DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; SPLENECTOMY; COHORT ANALYSIS; CORONARY DISEASE; HEART; NETHERLANDS; RADIATION INJURIES; RADIATION RESPONSE; STATISTICS AND NUMERICAL DATA; SURVIVOR;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEART; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RADIATION INJURIES; RISK FACTORS; SURVIVORS;

EID: 84955493946     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.4444     Document Type: Article

References (33)

1. IKNL: Dutch cancer figures. 2012; http://www.cijfersoverkanker.nl
2. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007
3. Galper SL, Yu JB, Mauch PM, et al: Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 117:412-418, 2011
4. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003
5. Myrehaug S, Pintilie M, Tsang R, et al: Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49:1486-1493, 2008
6. Ng AK: Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 154:23-31, 2011
7. van Nimwegen FA, Schaapveld M, Janus CPM, et al: Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175:1007-1017, 2015
8. Raemaekers JM, André MP, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
9. Specht L, Yahalom J, Illidge T, et al: ILROG: Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854-862, 2014
10. Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-998, 2013
11. Schellong G, Riepenhausen M, Bruch C, et al: Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55:1145-1152, 2010
12. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
13. Armstrong GT, Kawashima T, Leisenring W, et al: Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 32:1218-1227, 2014
14. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003
15. De Bruin ML, Dorresteijn LD, van't Veer MB, et al: Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101:928-937, 2009
16. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994
17. van Leeuwen FE, Klokman WJ, Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18:487-497, 2000
18. National Cancer Institute: Common terminology criteria for adverse events (CTCAE) version 4.0. Bethesda, MD, National Institutes of Health, 2009
19. van Nimwegen FA, Cutter DJ, Schaapveld M, et al: Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation x-rays. Int J Radiat Oncol Biol Phys 92:153-160, 2015
20. Joiner MC, Van der Kogel AJ: Basic Clinical Radiobiology (ed 4). London, UK, Hodder Arnold, 2009
21. Plummer M: Improved estimates of floating absolute risk. Stat Med 23:93-104, 2004
22. Tukenova M, Guibout C, Oberlin O, et al: Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308-1315, 2010
23. Cutter DJ, Schaapveld M, Darby SC, et al: Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 107:djv008, 2015
24. Maraldo MV, Brodin NP, Aznar MC, et al: Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 24:2113-2118, 2013
25. Maraldo MV, Brodin NP, Vogelius IR, et al: Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 83:1232-1237, 2012
26. Darby SC, Cutter DJ, Boerma M, et al: Radiation-related heart disease: Current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76:656-665, 2010
27. Paumier A, Ghalibafian M, Gilmore J, et al: Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 82:1522-1527, 2012
28. Petersen PM, Aznar MC, Berthelsen AK, et al: Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol 54:60-66, 2015
29. van der Pal HJ, van Dalen EC, van Delden E, et al: High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30:1429-1437, 2012
30. Swerdlow AJ, Higgins CD, Smith P, et al: Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 99:206-214, 2007
31. Armstrong GT, Oeffinger KC, Chen Y, et al: Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31:3673-3680, 2013
32. Jones LW, Liu Q, Armstrong GT, et al: Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: A report from the childhood cancer survivor study. J Clin Oncol 32:3643-3650, 2014
33. Ng A, Brock KK, Sharpe MB, et al: Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: a step toward understanding dose risk for late toxicity. Int J Radiat Oncol Biol Phys 84:e557-e563, 2012